Oncolytic viruses are attractive cancer therapeutics because of their unique mechanisms of tumor cell targeting and the absence of toxic side effects associated with current treatments. Bovine herpesvirus type 1 (BHV-1) is a species-specific herpesvirus that fails to induce cytopathic effects in normal human cells, but is capable of infecting and killing a variety of immortalized and transformed human cell types, including human breast tumor cell lines from luminal, basal A and basal B subtypes, representing a variety of receptor expression profiles. BHV-1 is capable of initiating replication in and killing both bulk and side population cells, the latter of which have enhanced tumor-initiating capacity. Despite the lack of a productive infection or secretion of cytotoxic factors, BHV-1 infection decreases cellular viability in long-term culture following low multiplicity of infection. Moreover, BHV-1-infected MCF7 cells are significantly diminished in their capacity to form tumors in vivo. Overall, these studies suggest that oncolytic BHV-1 targets bulk breast cancer cells and cancer-initiating cells from luminal and basal subtypes by a novel mechanism that is not contingent upon cellular receptor expression status.
INTRODUCTION
Recombinant and naturally occurring oncolytic viruses (OVs) preferentially replicate in and kill cancer cells while having minimal detrimental effects on normal cells by exploiting biochemical differences between normal and tumor cells. 1 Oncolytic virotherapy holds potential as a novel therapy given its two-pronged approach, the lytic destruction of cancer cells and induction of tumor-specific immune responses. 2 Although human viruses such as herpes simplex virus are safe and show signs of efficacy in clinical trials, [3] [4] [5] [6] pre-existing immunity and thus the treatment of metastatic disease warrants the development of wild-type, non-human viruses.
Bovine herpesvirus type 1 (BHV-1), a member of the Alphaherpesviridae subfamily, shares many similarities with herpes simplex virus. Although BHV-1 uses herpes simplex virus attachment and entry receptors heparan sulfate and nectin-1, it does not bind nectin-2 but instead binds CD155, a receptor associated with tumor cell migration and invasion that is upregulated in human cancers. [7] [8] [9] [10] Of clinical relevance is the narrow host range of BHV-1, as it is unable to productively infect normal murine and human cells. 11, 12 However, BHV-1 efficiently targets immortalized and transformed human cells. 12 Wild-type mice are not susceptible to infection with BHV-1; however, RAG-2 genedeleted mice lacking type I and II interferon (IFN) receptors die within several days of infection. 13 Unlike most naturally occurring OVs, however, permissivity of human cells to BHV-1 does not correlate with type I IFN signaling. 12 Cancer stem cells, also called cancer-initiating cells (CICs), are characterized by two properties, self-renewal and the ability to generate progeny consisting of all cell lineages contained within a tumor. 14, 15 Although CICs are typically thought to represent only 1-2% of total cells within a tumor mass, recent studies indicate that the frequency of CICs is variable. 16 Experimentally, CICs are often referred to as tumor-initiating cells due to their ability to support continual tumor growth in vivo. CICs possess properties that confer resistance to conventional therapies, including selfrenewal, differentiation, high proliferative capacity, resistance to apoptosis, active DNA repair mechanisms, relative quiescence and enhanced drug efflux. 17 Goodell et al. 18 first described a 'side population' (SP) of cells enriched for stem cell properties such as efflux of the DNA-binding dye Hoechst 33342, expression of stem cell markers and in vivo reconstitution abilities. 18 SPs have been identified in a variety of human tissues and cancers. 19, 20 An SP, ranging from 0.2 to 7.5%, has been described in the MCF7 human breast cancer cell line. This population is enriched for colony-forming ability, quiescence, CD44, efflux pump components, tumorsphere formation capacity and enhanced in vivo tumorigenesis. [21] [22] [23] [24] [25] [26] Thus, breast cancer SPs are prime targets for the investigation of new therapeutics capable of selectively eliminating tumorigenic cancer cells. The use of OVs to target CICs, and in particular breast CICs (BCICs), is attractive as OVs kill cancer cells through mechanisms distinct from conventional therapeutics. 27, 28 Recent studies have validated the ability of OVs to target CICs. 27, [29] [30] [31] We previously showed that BHV-1 targets immortalized and transformed human cells, but not normal cells. 12 Here, we report that BHV-1 targets bulk breast cancer cells and BCICs regardless of subtype or receptor status and reduces the sphere-and colony-forming ability of BCICs. Of interest, cell death does not require productive virus infection. Moreover, MCF7 cells exposed to BHV-1 are unable to initiate tumor formation in vivo. Collectively, these data suggest that BHV-1 possesses multiple strategies to target human BCICs to limit or prevent de novo tumor formation.
MATERIALS AND METHODS

Cell lines
All cell lines were maintained at 37 1C þ 5% CO 2 in medium supplemented with 2 mM L-glutamine, 100 U ml À 1 penicillin and 100 mg ml À 1 streptomycin. Human osteosarcoma cells (U2OS; American Type Culture Collection (ATCC), Manassas, VA, USA) were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS). Madin-Darby bovine kidney (MDBK) cells were obtained from Dr Vikram Misra (University of Saskatchewan, Saskatoon, SK, Canada) and were cultured in DMEM supplemented with 5% horse serum. Human breast adenocarcinoma cells (MCF7; ATCC) were cultured in high glucose DMEM (Gibco, Carlsbad, CA, USA) supplemented with 10% FBS. Additional human breast adenocarcinoma cell lines (HS-578T, MDA-MB-468 and SkBr3) were cultured in Roswell Park Memorial Institute medium (RPMI) supplemented with 10% FBS. MCF7 and HCC1954 spheres were maintained in stem cell medium comprised of DMEM-F12 (Gibco) supplemented with 10 ng ml À 1 basic fibroblast growth factor, 20 ng ml À 1 epidermal growth factor, 20 ng ml À 1 B27 and 1 mg ml À 1 heparin (Sigma, St Louis, MO, USA).
Viruses
BHV-1-expressing green fluorescent protein (BHV-1gfp) was a kind gift from Dr Gü nther Keil (Friedrich-Loeffler-Institut, Greifswald, Germany) and was propagated and titrated on MDBK cells. Virus preparations were purified by sucrose cushion. Specifically, 80% confluent 150 cm 2 dishes were infected with BHV-1gfp for 1 h at 37 1C at a multiplicity of infection (MOI) of 0.01 plaque-forming units per cell in serum-free DMEM. Following infection, cells were maintained in the appropriate medium and harvested 3 days post infection (dpi). Samples were centrifuged, supernatant collected and cell pellets resuspended in serum-free DMEM and stored at À 80 1C. Virus was isolated from supernatant fractions by ultracentrifugation at 25 000 r.p.m. for 2 h at 4 1C. Virus was isolated from cell pellets following three freeze-thaw and vortex cycles by Dounce homogenization and centrifugation at 1000 r.p.m. for 10 min at 4 1C. The virus-containing pellet was resuspended using the supernatant-associated fraction. The combined fractions were sonicated for 1 min and then purified by ultracentrifugation through a 36% sucrose gradient at 30 000 r.p.m. for 2 h at 4 1C. Purified virus was resuspended in serum-free DMEM, or phosphate-buffered saline for animal experiments, and stored at À 80 1C.
Measurement of virus replication and cellular viability
Cells were seeded into 96-well plates, and 1 day later, 90-95% confluent cell monolayers were infected with BHV-1gfp at the indicated MOI. One and two dpi plates were scanned on a Typhoon BioAnalyzer (GE Healthcare, Piscataway, NJ, USA) and virus replication was quantified as a function of GFP fluorescence, analyzed as a fold change over background and used to generate a heat map. Two dpi cellular viability was assessed using a Safire fluorescence spectrophotometer (Tecan, Männedorf, Switzerland). Measures of cellular metabolism and membrane integrity were assessed using alamarBlue and 5-carboxyfluorescein diacetate acetoxymethyl ester (CFDA-AM), respectively (Invitrogen, Grand Island, NY, USA). Cells were incubated with alamarBlue (5% (v v À 1 )) and CFDA-AM (4 mM) for 30 min at 37 1C, after which fluorescence was read. Data were analyzed relative to uninfected controls and corrected for background fluorescence.
Viral burst
Cells were infected with BHV-1gfp at an MOI of 3. Viral supernatants and infected cells were collected 1, 2 and 3 dpi. Samples were either freeze/ thawed three times or frozen once and sonicated for 1 min before centrifugation at 1000 r.p.m. for 10 min at 4 1C. Supernatant was collected and titrated by serial dilution in serum-free DMEM. Dilutions were applied to 90-95% confluent monolayers of MDBK for 1 h at 37 1C. MDBK monolayers were maintained in DMEM supplemented with 0.5% horse serum in 1% methyl cellulose. At 2 dpi cells were scanned on a Typhoon BioAnalyzer (GE Healthcare) and plaques were counted and viral burst determined.
Soluble factor cytotoxicity HS-578T was seeded into six-well plates, and 1 day later, 90-95% confluent monolayers were infected with BHV-1gfp at an MOI of 3. At 4, 24 and 48 hpi, supernatants were collected and transferred to naive HS-578T and MDBK monolayers. Cellular viability was assessed 2 dpi using alamarBlue and CFDA-AM.
SP cell sorting
Cells were trypsinized, filtered through a 40 mm mesh and resuspended in DMEM supplemented with 2% FBS and 10 mM HEPES buffer at 10 6 cells per ml. Control samples were incubated with 50 mM reserpine (Sigma) for 30 min at 37 1C. All samples were then incubated with 5 mg ml À 1 Hoechst 33342 dye for 90 min in a 37 1C water bath with intermittent shaking. Following incubation, cells were washed and resuspended in Hank's balanced salt solution buffer supplemented with 2% FBS, 10 mM HEPES buffer, 2 mg ml À 1 propidium iodide (Sigma) and kept on ice. Before flow analysis, cells were filtered through a 40 mm mesh to obtain a single-cell suspension. Sorting was performed using a FACSVantage SE (Becton Dickinson, Franklin Lakes, NJ, USA) with FACSDiva Option. A wavelength of 350 nm was used to excite the Hoechst 33342, while Hoechst blue was detected at 424/44 nm and Hoechst red at 675LP. Channels were separated by a 640LP dichromic beam splitter, and sorting was carried out at 16c sheath pressure using a 100 mm nozzle. The SP population was defined as cells diminished in the presence of reserpine. Data were analyzed using the Flow Jo 8. Sphere-forming assay Spheres were dissociated by trypsinization at 37 1C for 2 min with pipetting and resuspended in stem cell medium. Cells were plated at 3.0 Â 10 4 cells per ml and mock-or BHV-1gfp-infected at MOIs of 1, 3, 5 or 10 for 30 min at 37 1C. Following infection, cells were resuspended in stem cell medium and transferred to 24-well plates. The number of spheres for each well was counted after 4 days of culture and compared between mock-and BHV-1gfp-infected groups.
Colony-forming assay
Spheres were dissociated by trypsinization at 37 1C for 2 min with pipetting and resuspended in complete medium. Cells were plated into 96-well plates at a density of 3.0 Â 10 4 cells per ml and mock-or BHV-1gfp-infected at MOIs of 1, 3, 5 and 10 for 45 min at 37 1C. Following infection, cells were collected and resuspended in complete medium and seeded into 10 mm 2 plates and cultured for 10 days. Cells were then washed with phosphatebuffered saline, fixed in methanol for 2 min and Giemsa stained. Colonies were counted and compared between mock-and BHV-1gfp-infected groups.
In vivo tumor analysis MCF7 cells were either mock infected or infected with BHV-1gfp at an MOI of 3. Cells were incubated for 3 h at 37 1C, trypsinized, centrifuged at 1000 r.p.m. for 10 min at 4 1C and resuspended in a 1:1 phosphate-buffered saline/Matrigel mixture. Anesthetized 5-week-old female NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ (nonobese diabetic/severe combined immune deficiency gamma (NSG)) mice (Jackson Laboratory, Bar Harbor, ME, USA) were injected subcutaneously with 10 6 cells resuspended in 200 ml of phosphatebuffered saline/Matrigel one day following subcutaneous implantation of slow-release 17b-estradiol pellets (1.5 mg per pellet, 60-day release; Innovative Research of America, Sarasota, FL, USA) via trocar. Tumor growth was monitored every 2 to 3 days. Tumor volume was determined by digital caliper measurement and calculated using: (4/3)p (length/2) (width/2) 
RESULTS
Exposure to BHV-1 reduces cellular viability in multiple breast cancer cell types The in vitro oncolytic capacity of BHV-1 has been demonstrated in several human breast cancer cell lines. 12 Breast cancer treatments are designed based on tumor stage, grade and molecular profile, including tumor subtype and receptor status. Multidrug resistance and subsequent patient relapse warrants the development of novel and broadly applicable treatment strategies. Breast cancer cell lines representing basal A, basal B and luminal subtypes, as well as varying estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 expressions were included in our screen ( Table 1 ). The capacity of BHV-1gfp to initiate replication in and decrease cellular viability of breast cancer cells was determined. The initiation of virus replication, as a function of GFP fluorescence, was quantified 2 dpi and is represented as a fold change over background. These data were used to generate a heat map. Cellular viability, in terms of cellular metabolism and membrane integrity, was quantified 2 dpi and is represented as a fold change relative to uninfected cells. Initiation of virus replication increased with increasing MOI, which resulted in a coinciding decrease in both measures of cellular viability, with the exception of MDA-MB-436, which did not show a decrease in either measure of cellular viability ( Figure 1 ). Interestingly, increases in virus replication did not always correlate with decreases in cellular viability. Although low levels of virus replication were observed on BT-549, Hs-578T and HCC1954, decreases in both measures of cellular viability occurred ( Figure 1 ).
The ability of BHV-1gfp to replicate productively in these cells was assessed by determining the number of infectious virus particles produced per cell. The bovine cell line MDBK was used as a positive control. Interestingly, the initiation of virus replication did not yield a burst of infectious virus in these cell lines, with the exception of MCF7 and SK-BR-3 ( Figure 2 and data not shown). Collectively, these data suggest that exposure to BHV-1 is sufficient to reduce the cellular viability of a wide variety of breast cancer cell types.
Breast cancer cell death is not the result of a soluble cytotoxic factor Because of the absence of a productive infection in Hs-578T cells, we were surprised to observe significant cellular death 10 dpi with BHV-1gfp at an MOI as low as 0.1 and at 20 dpi at an MOI of 0.01 (Figure 3a) . Thus, we investigated whether a soluble cytotoxic byproduct of infection contributes to Hs-578T cellular death. Supernatant was collected from BHV-1gfp-infected Hs-578T cells at 24 and 48 h following infection at an MOI of 3, applied to naive Hs-578T cells and cellular viability was assessed 2 days posttreatment. We failed to detect a significant decrease in cellular metabolism and membrane integrity (Figure 3b ). These data suggest that Hs-578T cellular death does not occur because of the presence of a soluble cytotoxic by-product of infection. Transfer of supernatants to naive permissive MDBK cells also failed to alter cellular viability and no hallmarks of infection were observed (data not shown), confirming that Hs-578T cells secrete neither a soluble cytotoxic factor nor infectious virus particles. Instead, these data suggest that direct exposure of Hs-578T cells to BHV-1gfp induces cell death. Similar results were observed in additional breast cancer cell lines (data not shown).
BHV-1 exposure kills BCICs Breast cancer relapse and metastasis has been, in part, attributed to the presence of BCICs. BCICs are highly tumorigenic and possess the ability to self-renew, form differentiated progeny and resist conventional therapeutics, such as radiation and chemotherapy. 27, 28 Targeting bulk breast tumor cells and BCICs may result in sustained tumor remission and increased patient survival. To address whether BCICs from luminal and basal subtypes are permissive to BHV-1gfp infection, SP cells were isolated from MCF7 (luminal), Hs-578T (basal B) and MDA-MB-468 (basal A) cultures, immediately plated following sorting, and infected with BHV-1gfp at MOIs of 3 and 10. As accumulation of Hoechst 33342 dye is toxic, sorted non-SP cells were not assessed. Initiation of virus replication and a decrease in both measures of cellular viability were observed in the SP populations isolated from MCF7 ( Figure 4a ) and Hs-578T (data not shown). Although GFP fluorescence was not detected in MDA-MB-468 SP cells, a decrease in cellular viability occurred (Figure 4b ). Cytopathic effects were observed at all MOIs tested (data not shown). The ability of BHV1gfp to replicate productively in MCF7 BCICs was assessed by determining the number of infectious virus particles produced per cell. The viral burst of BHV-1gfp was not significant in MCF7 SP cells, indicating that the presence of an appreciable viral burst is not required for MCF7 BCIC death (Figure 4c ).
BHV-1 reduces the self-renewal and differentiation of human BCICs
Sphere-and colony-forming assays can be used to assess selfrenewal and differentiation of BCICs, respectively. Therefore, these 
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Integrity Cell Line methods were employed to analyze the effect of BHV-1gfp exposure on the self-renewal and differentiation of MCF-7 and HCC1954 BCICs. MCF7 and HCC1954 tumorspheres were dissociated and mock-or BHV-1gfp-infected at MOIs of 1, 3, 5 and 10.
Spheres were counted at 4 dpi and colonies at 10 dpi and compared between mock-and BHV-1gfp-infected groups. The sphere-forming ability of MCF7 and HCC1954 decreased by B48% and B69%, respectively, and colony formation decreased by B39% and B93%, respectively, as the result of BHV-1gfp infection using an MOI as low as 3 ( Figure 5 ). Taken together, these data indicate that BHV-1gfp reduces both the self-renewal and differentiation of BCICs from luminal and basal breast cancer cell lines.
BHV-1-exposed MCF7 cells have reduced tumor-forming ability in vivo
Our data suggest that BHV-1gfp initiates replication in and reduces cellular viability of MCF7 SP cells, despite the lack of productive infection. MCF7 SP cells have been described as having increased tumor-forming ability in vivo. [21] [22] [23] To confirm that exposure to BHV-1gfp reduces the in vivo tumor-forming ability of MCF7 SP cells, bulk MCF7 cells were mock-or BHV-1gfp-infected and injected subcutaneously into NSG mice. Tumor volumes in mice injected with BHV-1gfp-infected cells were significantly less than mock-infected for the duration of the experiment (Po0.01), which was performed for 66 days to ensure the effect was sustained ( Figure 6 ). Overall, these data indicate that exposure of bulk MCF7 cells to BHV-1gfp leads to a reduction in tumor formation in vivo, consistent with the ability of BHV-1gfp to reduce cellular viability in vitro.
DISCUSSION
Although somewhat controversial, it is generally accepted that a population of breast cancer cells, referred to as BCICs, possess increased tumorigenicity and enhanced resistance to conventional cancer therapy. BCICs are thought to be largely responsible for patient relapse and development of metastatic disease; therefore, development of treatment strategies, which kill these cells, would lead to sustained and increased patient survival. The depletion of BCICs using OVs is an attractive avenue of cancer therapy because of the ability of OVs to evade host resistance mechanisms, their utility as delivery vehicles for therapeutic transgenes that target the tumor-propagating phenotype of BCICs and their resistance to commonly used chemotherapeutics, permitting combination therapy approaches. 27 Oncolytic reovirus infects BCICs and bulk cells within tumors, and replicates to similar levels in both cell types eliciting cellular death via apoptosis. 29, 32 Similarly, oncolytic adenovirus targets CD44 þ CD24 À /low breast cancer cells and shows efficacy in animal models of both advanced local and metastatic breast cancer. 30, 31 Because of their neurotropic nature, herpes simplex virus oncolytic vectors effectively target glioma CICs. 27, 33 While these vectors show promise as OVs in preclinical and clinical trials, an inherent disadvantage of using human confound comprehensive analysis of the progression of infection in SP versus non-SP cells. Several studies have examined factors dictating sensitivity of CICs to OV infection. Specific to BCICs, defects in the induction of the type I IFN response were found to mediate susceptibility to oncolytic adenovirus. 34 Although many naturally occurring OVs exploit defects in IFN signaling to replicate, BHV-1 replication does not depend on type I IFN status. 12 Moreover, cells that are immortalized, but not transformed, are also susceptible to BHV-1, 12 , suggesting that BHV-1 may target preneoplastic cells. Overall, CIC sensitivity to OV infection depends on the virus used and the mutations present. Understanding stem cell biology in the context of OV infection will allow for development of more effective immunotherapies to target CICs.
Despite the lack of productive infection, BHV-1-infected cultures showed significant cell death in long-term culture, even following low MOI infection. The observed cell death could not be explained by the production of a soluble cytotoxic factor, suggesting that BHV-1 elicits cell death through a different mechanism. These data suggest that the presence of a permissive cellular environment is not required for BHV-1 to elicit oncolytic activity.
Although lytic infection of cells with herpesviruses typically lead to the induction of apoptosis and other forms of cell death, viral infection can also influence cell status through epigenetic alterations and microRNA (miRNA) production. Epigenetic modifications can influence imprinting, germ line silencing, DNA rearrangements, overall chromosome stability and stem cell division. 35 It is well appreciated that disruption of epigenetic processes can lead to altered gene function and tumorigenesis and that epigenetic changes of both viral and host genomes in virally infected cells can affect malignant cellular transformation. 36, 37 Herpesvirus in particular have been shown to elicit host epigenetic changes, in part by encoding genes that alter host methylation and histone deacetylation. [38] [39] [40] Herpesviruses are also known for their expression of high levels of multiple miRNA species that regulate viral replication and pathogenesis and for their ability to reshape the pattern of host miRNA expression. 41 Indeed, the human herpesvirus Kaposi's sarcoma-associated herpesvirus encodes an miRNA that regulates global cellular epigenetic reprogramming. 42 As both epigenetic modifications and miRNAs regulate CICs [43] [44] [45] , it is plausible that infection of BCICs with BHV-1 induces cellular alterations that rendered them less efficient in tumor initiation, despite maintaining a population of cells with efflux properties. Moreover, under conditions where we observed cell death in long-term culture following a low MOI infection, it is possible that BHV-1-induced alterations of the cellular genome led to cell death. Although an MOI of 0.1 suggests that only 1 in 10 cells received an infectious or plaque-forming virus particle, given that a typical particle to plaque-forming unit ratio for wild-type alphaherpesviruses is B100, it is possible that each cell in the culture was exposed to at least one virus particle. It will be intriguing to elucidate how exposure of breast cancer cells to BHV-1 elicits cell death in the absence of productive infection.
Overall, these data have implications for breast cancer therapy. Given the strict species specificity of BHV-1, the lack of neutralizing antibodies within the human population and the inability of BHV-1 to induce toxicity in healthy cells, 12 BHV-1 is an excellent candidate for oncolytic virotherapy requiring intravenous administration to reach difficult to access and/or metastasized tumors. Of particular interest is the ability of BHV-1 to kill bulk breast cancer cells and BCICs irrespective of tumor subtype or receptor status. In contrast, conventional treatments are designed based on tumor stage, grade and molecular profile, including tumor subtype and receptor status. Tumor heterogeneity, both within the tumor and between patients, represents a significant roadblock to the efficacy of current treatment strategies. Furthermore, multidrug resistance and subsequent patient relapse prevent lasting patient cures. The ability of BHV-1 to infect and kill BCICs has important implications for the prevention of metastases and relapses. Moreover, BHV-1-exposed BCICs are restricted in their capacity to initiate tumor formation in vivo. Our study did not evaluate the efficacy of BHV-1 against established human breast tumors; the host immune response plays a pivotal role in oncolytic virotherapy, confounding the use of immunedeficient mice. [46] [47] [48] Despite advances in the isolation and molecular characterization of murine BCICs, their roles as putative tumor-initiating cells within the context of spontaneous and genetically engineered murine models of BC remain unclear. 49, 50 Therefore, data obtained using these models may not be indicative of results in humans. Future studies aimed at understanding the mechanism of BHV-1-induced cell death in human breast cancer cells will provide valuable information on basic tumor biology and enable the development of novel therapies with the ability to overcome the specificity of currently used treatments.
